The pharmaceutical company Avia Pharma has acquired the Swedish pharmaceutical company Pharmaprim, with a product portfolio consisting of drugs in urology, rheumatology and endocrinology.
On December 31, 2019, Avia Pharma acquired the rights to ACO Karbamid and ACO Glycerol from Perrigo.
Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.
Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.
Currently there are two Vitamin D drops being sold on the Swedish market. ACO Vitamin D drops does not contain palm oil but the competing product does.
Following a very strong sales increase for all products, Omega Pharma and Avia Pharma has decided to expand their co-operation.
Avia Pharma appoints Marie Wikman as Business Unit Director OTC.
Avia Pharma and Dr Pfleger have entered into a long-term license agreement for Spasmex (Trospium) and Vagitin (Nystatin). The license for Spasmex covers Sweden and Norway and the license for Vagitin covers all Nordic countries.
The new “Kloka Listan” from SLL has updated its recommendation for iron supplements. It previously stated, incorrectly, that Niferex had fewer adverse events than Duroferon.
Avia Pharma has entered into an in-licensing agreement with Omega Pharma for the following products; Duroferon, Ferro Duretter, Minifom, D-vitamin Olja ACO, D-vitamin Vatten ACO, Dunmedic Vitamin D-olja and Nix.Under the agreement Avia Pharma will handle all commercial aspects of the products.